Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vyxeos (Jazz Pharmaceuticals plc)
- Development stage
- Phase 4
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Vyxeos (CPX-351) is a liposomal formulation of the chemotherapy agents cytarabine and daunorubicin, encapsulated in a fixed 5:1 molar ratio. This specific ratio is designed to maximize synergistic antineoplastic activity while minimizing toxicity. Daunorubicin, an anthracycline, acts by intercalating into DNA and inhibiting DNA topoisomerase II, while cytarabine, a nucleoside analog, inhibits DNA synthesis by competing with cytidine for incorporation into DNA. Originally developed by Celator Pharmaceuticals and later acquired by Jazz Pharmaceuticals, Vyxeos is FDA-approved for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). The drug is also being investigated in pediatric and young adult populations for a variety of relapsed or refractory hematologic malignancies, including acute lymphoblastic leukemia and various types of lymphoma, through clinical trials such as those led by Cincinnati Children's Hospital Medical Center.
- Brand names
- Vyxeos
- Other names
- liposomal cytarabine and daunorubicincytarabine-daunorubicin liposome
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on Vyxeos (Jazz Pharmaceuticals plc).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vyxeos (Jazz Pharmaceuticals plc).